Immunomedics

Immunomedics
Industry	Biotechnology
Fate	Acquired by Gilead Sciences
Founded	July 1982
Founder	David M. Goldenberg
Defunct	October 23, 2020
Headquarters	Morris Plains, New Jersey
Website	www.immunomedics.com

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]

History

Immunomedics was founded in July 1982 by David M. Goldenberg.[2]

Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]

In October 2020, Gilead Sciences acquired the company.[1]

Drugs

Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.[5] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.[6]
Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.
IMMU-114 is an anti-HLA-DR for hematological cancers.[7]

References

"Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.
Feuerstein, Adam (January 25, 2017). "Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder". TheStreet.com.
Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.
"Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.
"FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020.
LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.
Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[gilead-1] "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.

[2] Feuerstein, Adam (January 25, 2017). "Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder". TheStreet.com.

[3] Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.

[4] "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.

[5] "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020.

[6] LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.

[7] Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature.